Abstract:Alzheimer's Disease (AD) and Parkinson's Disease (PD) represent two among the most frequent neurodegenerative diseases worldwide. A common hallmark of these pathologies is the misfolding and consequent aggregation of amyloid proteins into soluble oligomers and insoluble β-sheet-rich fibrils, which ultimately lead to neurotoxicity and cell death. After a hundred years of research on the subject, this is the only reliable histopathological feature in our hands. Since AD and PD are diagnosed only once neuronal death and the first symptoms have appeared, the early detection of these diseases is currently impossible. At present, there is no effective drug available, and patients are left with symptomatic and inconclusive therapies. Several reasons could be associated with the lack of effective therapeutic treatments. One of the most important factors is the lack of selective probes capable of detecting, as early as possible, the most toxic amyloid species involved in the onset of these pathologies. In this regard, chemical probes able to detect and distinguish among different amyloid aggregates are urgently needed. In this article, we will review and put into perspective results from ex vivo and in vivo studies performed on compounds specifically interacting with such early species. Following a general overview on the three different amyloid proteins leading to insoluble β-sheet-rich amyloid deposits (amyloid β1-42 peptide, Tau, and α-synuclein), a list of the advantages and disadvantages of the approaches employed to date is discussed, with particular attention paid to the translation of fluorescence imaging into clinical applications. Furthermore, we also discuss how the progress achieved in detecting the amyloids of one neurodegenerative disease could be leveraged for research into another amyloidosis. As evidenced by a critical analysis of the state of the art, substantial work still needs to be conducted. Indeed, the early diagnosis of neurodegenerative diseases is a priority, and we believe that this review could be a useful tool for better investigating this field.

Shedding Light on Alzheimer's Disease: Recent Advances in Highly Selective Fluorescent Probes

Current strategies for the development of fluorescence-based molecular probes for visualizing the enzymes and proteins associated with Alzheimer’s disease

Application of Biomarker-Derived Fluorescent Probes for the Detection of Alzheimer's Disease

Advances in development of fluorescent probes for detecting amyloid-β aggregates

Development of Near-Infrared Fluorescent Probes for Use in Alzheimer’s Disease Diagnosis

Research Progress Of Multi-Functional Fluorescent Probes For Alzheimer'S Disease Monitoring

Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease.

Development of Near-Infrared Fluorescent Probes for Use in Alzheimers Disease Diagnosis

Fluorescent Imaging of Amyloid-β Deposits in Brain: An Overview of Probe Development and a Highlight of the Applications for in vivo Imaging.

Targeting Β-Amyloid Plaques and Oligomers: Development of Near-Ir Fluorescence Imaging Probes.

Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers

Dual-functional AIE fluorescent probes for imaging -amyloid plaques and lipid droplets

Rational design synthesis and evaluation of a novel near-infrared fluorescent probe for selective imaging of amyloid-β aggregates in Alzheimer's disease

Enhanced Detection Specificity and Sensitivity of Alzheimer's Disease Using Amyloid-β-Targeted Quantum Dots.

Recent Advances in Fabricating the Multifunctional A beta Small Organic Molecule Probes for Theranostic Application

Probing Alzheimer's pathology: Exploring the next generation of FDDNP analogues for amyloid β detection

Near-infrared Fluorescent Probes for Imaging of Amyloid Plaques in Alzheimer׳s Disease.

Molecular Imaging of Fluorinated Probes for Tau Protein and Amyloid-β Detection

Iterative Design of Near-Infrared Fluorescent Probes for Early Diagnosis of Alzheimer's Disease by Targeting Aβ Oligomers

Progress of Near-Infrared Fluorescent Probes for beta-Amyloid Plaques in the Brain

Highly Sensitive Near-Infrared Fluorophores for in Vivo Detection of Amyloid-β Plaques in Alzheimer’s Disease